AGM/EGMMay 18, 2026, 02:21 PM
Ultragenyx Stockholders Elect Directors, Approve Incentive Plan
AI Summary
Ultragenyx Pharmaceutical Inc. held its Annual Meeting of Stockholders on May 14, 2026. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting and approved the Third Amended and Restated 2023 Incentive Plan. Additionally, the selection of Ernst & Young LLP as the independent registered accounting firm for 2026 was ratified, and executive compensation was approved on an advisory basis.
Key Highlights
- Class I Directors Emil D. Kakkis, Shehnaaz Suliman, and Daniel G. Welch were elected until the 2029 Annual Meeting.
- The Third Amended and Restated 2023 Incentive Plan was approved with 50,659,150 votes for.
- Stockholders ratified Ernst & Young LLP as the independent auditor for 2026 with 84,551,399 votes for.
- Executive compensation was approved on an advisory basis with 70,945,277 votes for.
- 98,317,221 shares were outstanding and entitled to vote as of the March 23, 2026 record date.
- A total of 84,786,388 shares were represented at the Annual Meeting.
Price Impact
More from RARE